Bora Pharmaceuticals Co., Ltd./ADR
No enriched coverage for $BORAY in the last 7 days.
No SEC Form 4 filings for $BORAY in the last 30 days.
See all $BORAY insider activity →Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.
Closing adds 20,000L single-use bioreactor DS capacity and expands Bora Biologics’ US footprint, supporting near-term capacity utilization and longer-term CDMO revenue visibility.
alphai scores every news story that mentions BORAY with an AI model for sentiment and relevance, and aggregates insider trades from Bora Pharmaceuticals Co., Ltd./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bora Pharmaceuticals (TWSE:6472; OTCQX:BORAY) said it completed its acquisition of MacroGenics’ GMP biologics drug-substance manufacturing operations in Rockville, MD, plus a Frederick, MD warehousing center, for $122.5M via Bora Biologics USA. Bora also signed a long-term CDMO service agreement with MacroGenics and now has 20,000L US SUB capacity across Rockville and San Diego.
5 min read
